Pamiparib clinical trials
Also written BGB-290.
How each study uses pamiparib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pamiparib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2022 (10)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 10 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 18
BeiGene (9) · Sun Yat-sen University (3) · Bai-Rong Xia (1) · University of California, San Francisco (1) · Zhejiang Cancer Hospital (1) · BeOne Medicines (1) · Nader Sanai (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Tislelizumab (5) · Surufatinib (2) · Sitravatinib (1) · Hpk1 Inhibitor BGB-15025 (1) · Zanidatamab (1) · Olaparib (1) · Bevacizumab (1) · Albumin-Bound Paclitaxel (1)
Related medicines
As reviewed, each with the page that says it.
- One of PARP inhibitors source
Studies
Open first, then newest update. How each study uses pamiparib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 28
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck CancerRecruitingPhase 1University of ChicagoNCT05526924Written as PamiparibHow we know
- Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)RecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06387056Written as PamiparibHow we know
- A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair DefectsRecruitingPhase 2Peter MacCallum Cancer Centre, AustraliaNCT04985721Written as PamiparibHow we know
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerActive, not recruitingPhase 2Bai-Rong XiaNCT05652283Written as PamiparibHow we know
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedPhase 3BeOne MedicinesNCT04164199Written as PamiparibHow we know
- Study of Pamiparib in Newly Diagnosed and rGBMCompletedEarly Phase 1Nader SanaiNCT04614909Written as PamiparibHow we know
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid TumorsCompletedPhase 1M.D. Anderson Cancer CenterNCT05038839Written as PamiparibHow we know
- Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerActive, not recruitingPhase 3BeiGeneNCT03519230Written as Pamiparib capsuleHow we know
- BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV GliomasActive, not recruitingPhase 1University of California, San FranciscoNCT03749187Written as PARP Inhibitor BGB-290How we know
- Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian CancerCompletedPhase 1/2Sun Yat-sen UniversityNCT05494580Written as PamiparibHow we know
- Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian CancerCompletedPhase 2Tongji HospitalNCT05044871Written as PamiparibHow we know
- Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid TumorsCompletedPhase 1/2BeiGeneNCT03333915Written as PamiparibHow we know
- BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 MutationsCompletedPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03914742Written as PARP Inhibitor BGB-290How we know
- Phase 1a/1b BGB-290 for Advanced Solid Tumors.CompletedPhase 1BeiGeneNCT02361723Written as BGB-290How we know
- Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1BeiGeneNCT03150810Written as PamiparibHow we know
- Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in ChinaCompletedPhase 2BeiGeneNCT03575065Written as BGB-290How we know
- Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedPhase 2BeiGeneNCT03427814Written as PamiparibHow we know
- Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With CancerCompletedPhase 1BeiGeneNCT03994211Written as pamiparib 60 mgHow we know
- A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor ExposureActive, not recruitingPhase 2Zhejiang Cancer HospitalNCT05489926Written as PamiparibHow we know
- Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell CancerWithdrawnPhase 2Jonsson Comprehensive Cancer CenterNCT04603365Written as PamiparibHow we know
See all 28 studies that test pamiparib →
Given beside what is tested · 3 — pamiparib is usual care or a partner of the new treatment
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as PamiparibHow we know
- Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung CancerRecruitingPhase 1Affiliated Hospital of Jiangnan UniversityNCT05573373Written as ParimparibHow we know
- A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent GlioblastomaCompletedPhase 1/2BeiGene USA, Inc.NCT03150862Written as PamiparibHow we know
Codes
What other systems call pamiparib · ClinicalTrials.gg INT001345
- MeSH (NLM) C000707927pamiparibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8375F9S90CPAMIPARIBConfirmed FDA, NLM, Wikidata
- Wikidata Q125351134pamiparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C120553PamiparibOne source FDA
- DrugBank DB14769One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707927 | pamiparib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8375F9S90C | PAMIPARIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q125351134 | pamiparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C120553 | Pamiparib | One source FDA |
| DrugBank | DB14769 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.